FI54479B - Analogifoerfarande foer framstaellning av terapeutiskt verksamma fenylsubstituerade piperazinylalkylaminouraciler-uraciletrar eller -uraciltioetrar - Google Patents

Analogifoerfarande foer framstaellning av terapeutiskt verksamma fenylsubstituerade piperazinylalkylaminouraciler-uraciletrar eller -uraciltioetrar

Info

Publication number
FI54479B
FI54479B FI2271/70A FI227170A FI54479B FI 54479 B FI54479 B FI 54479B FI 2271/70 A FI2271/70 A FI 2271/70A FI 227170 A FI227170 A FI 227170A FI 54479 B FI54479 B FI 54479B
Authority
FI
Finland
Prior art keywords
analogification
verification
therapeutic
pharmaceutical
frequency
Prior art date
Application number
FI2271/70A
Other languages
English (en)
Other versions
FI54479C (fi
Inventor
Wolfgang Pruesse
Kurt Klemm
Wolfgang Schoetensack
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of FI54479B publication Critical patent/FI54479B/fi
Application granted granted Critical
Publication of FI54479C publication Critical patent/FI54479C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
FI2271/70A 1969-08-20 1970-08-19 Analogifoerfarande foer framstaellning av terapeutiskt verksamma fenylsubstituerade piperazinylalkylaminouraciler -uraciletrar eller -uraciltioetrar FI54479C (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1942405A DE1942405C3 (de) 1969-08-20 1969-08-20 Arylsubstituierte Piperazinylpropylenaminouracile

Publications (2)

Publication Number Publication Date
FI54479B true FI54479B (fi) 1978-08-31
FI54479C FI54479C (fi) 1978-12-11

Family

ID=5743321

Family Applications (1)

Application Number Title Priority Date Filing Date
FI2271/70A FI54479C (fi) 1969-08-20 1970-08-19 Analogifoerfarande foer framstaellning av terapeutiskt verksamma fenylsubstituerade piperazinylalkylaminouraciler -uraciletrar eller -uraciltioetrar

Country Status (24)

Country Link
US (2) US3957786A (fi)
AT (2) AT302359B (fi)
BE (1) BE755015A (fi)
BG (3) BG17796A3 (fi)
BR (1) BR6915466D0 (fi)
CA (1) CA956944A (fi)
CH (2) CH582173A5 (fi)
DE (1) DE1942405C3 (fi)
DK (1) DK124031B (fi)
ES (1) ES382842A1 (fi)
FI (1) FI54479C (fi)
FR (1) FR2073300B1 (fi)
GB (1) GB1309324A (fi)
HK (1) HK23678A (fi)
HU (1) HU163664B (fi)
IE (1) IE35177B1 (fi)
IL (1) IL35121A (fi)
LU (1) LU61527A1 (fi)
NL (1) NL155014B (fi)
NO (1) NO129148B (fi)
SE (1) SE386448B (fi)
SU (1) SU399130A3 (fi)
YU (2) YU36509B (fi)
ZA (1) ZA705729B (fi)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2329399A1 (de) * 1973-06-08 1975-01-02 Wuelfing J A Fa 4-alkyl-aminouracile, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
LU74319A1 (fi) * 1976-02-09 1977-08-19
DE3326118A1 (de) 1982-08-02 1984-02-09 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Pyridopyrimidintrione, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
CA2024428A1 (en) * 1989-09-06 1991-03-07 Masayuki Ishikawa Agent for treating urinary obstruction
AU7078691A (en) 1990-02-01 1991-08-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Use of urapidile and derivatives for treating arteriosclerotic diseases
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
WO1996017831A1 (de) * 1994-12-07 1996-06-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Uracilderivate
EP1604653A1 (en) 1998-09-30 2005-12-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
JP2004517081A (ja) * 2000-11-29 2004-06-10 イーライ・リリー・アンド・カンパニー １−（２−ｍ−メタンスルホンアミドフェニルエチル）−４−（ｍ−トリフルオロメチルフェニル）ピペラジンならびにその医薬的に許容しうる塩および溶媒和物
WO2003000664A1 (de) * 2001-06-22 2003-01-03 Bayer Aktiengesellschaft Uracilderivative und ihre verwendung bei der behandlung bakterieller erkrankungen
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
AU2004279336A1 (en) 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20060264442A1 (en) * 2005-05-18 2006-11-23 Allergan, Inc. Methods for the treatment of ocular and neurodegenerative conditions in a mammal
CN101200451B (zh) * 2006-12-15 2010-12-15 重庆药友制药有限责任公司 一种盐酸乌拉地尔的制备方法
CN102295607B (zh) * 2011-06-16 2013-04-17 郑州大学 乌拉地尔的逆相转移催化制备方法
KR102638538B1 (ko) 2021-12-28 2024-02-20 주식회사 한서켐 우라피딜 제조 중간체의 제조방법
CN115477616A (zh) * 2022-09-27 2022-12-16 河北广祥制药有限公司 一种乌拉地尔杂质的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2567651A (en) * 1951-09-11 J-dialkyl-g-amino-l

Also Published As

Publication number Publication date
HK23678A (en) 1978-05-12
SU399130A3 (fi) 1973-09-27
DE1942405B2 (de) 1973-10-31
FR2073300B1 (fi) 1974-02-01
US3957786A (en) 1976-05-18
DE1942405A1 (de) 1971-09-16
IE35177B1 (en) 1975-12-10
IE35177L (en) 1971-02-20
GB1309324A (en) 1973-03-07
IL35121A (en) 1974-03-14
HU163664B (fi) 1973-10-27
SU363248A3 (fi) 1972-12-30
NO129148B (fi) 1974-03-04
BG17795A3 (fi) 1973-12-25
YU207670A (en) 1982-02-25
SE386448B (sv) 1976-08-09
BE755015A (fr) 1971-02-01
YU36509B (en) 1984-02-29
CH582173A5 (fi) 1976-11-30
ES382842A1 (es) 1973-02-16
YU36518B (en) 1984-02-29
BG17796A3 (fi) 1973-12-25
DE1942405C3 (de) 1974-05-30
AT302359B (de) 1972-10-10
BR6915466D0 (pt) 1973-05-15
DK124031B (da) 1972-09-04
IL35121A0 (en) 1970-10-30
ZA705729B (en) 1972-03-29
CA956944A (en) 1974-10-29
LU61527A1 (fi) 1971-06-22
FI54479C (fi) 1978-12-11
FR2073300A1 (fi) 1971-10-01
YU203979A (en) 1982-02-25
CH551990A (de) 1974-07-31
NL155014B (nl) 1977-11-15
US4067982A (en) 1978-01-10
BG17585A3 (fi) 1973-11-10
AT318651B (de) 1974-11-11
NL7012364A (fi) 1971-02-23

Similar Documents

Publication Publication Date Title
NO138807C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivr e 3-merkaptotiadiazol- eller merkaptotetrazol-cefalosporine
FI55832C (fi) Foerfarande foer framstaellning av terapeutiskt verksamma nya alfa-substituerade bensylimidazoler
FI54479B (fi) Analogifoerfarande foer framstaellning av terapeutiskt verksamma fenylsubstituerade piperazinylalkylaminouraciler-uraciletrar eller -uraciltioetrar
FI54301C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara kinazolinderivat
NO146189C (no) Anordning for fremstilling av kunst-kull-formlegemer
FI53897B (fi) Ljuskaensliga foereningar och foerfarande foer framstaellning av dessa
FI55184B (fi) Foerfarande foer framstaellning av terapeutiskt verksamma fenyl-2-pyrrolidinoner samt deras isomerer
FI54099B (fi) Analogifoerfarande foer framstaellning av nya terapeutiskt aktiva fenylalkansyror
SE396387B (sv) Forfarande for framstellning av 1-(2-karboxikromonyloxi)-2-hydroxi-3-p-cyanfenoxi-propaner med terapentisk verkan
FI55507C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 1 2 5-tiadiazoler
SE402451B (sv) Forfarande for framstellning av 14-desoxi-14-acetoximutilin
FI54602B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 6-amidinopenicillansyraderivat
FI55988C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara o-acylfenoletanolaminer
SE380800B (sv) Analogiforfarande for framstellning av dibensodiazepiner och pyridobensodiazepiner
FI53700C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara diaminopropiofenonderivat
FI55338C (fi) Foerfarande foer framstaellning av terapeutiskt verksamma n-metyl-imidazoler
TR16868A (tr) Islah edilmis uere-formaldehid koepuek maddelerinin imaline mahsus usul
SE394668B (sv) Forfarande for framstellning av 2-etylhexan-1-al
SE380753B (sv) Forfarande och anordning for framstellning av stavelement for rymdfackverk
SE393980B (sv) Forfarande for framstellning av 5-(och7-) bensoylindolin-2-oner med terapeutisk verkan
SE382324B (sv) Sett att framstella amiderade fenoxipropanolaminderivat med terapeutisk anvendbarhet
FI56179C (fi) Foerfarande foer framstaellning av terapeutiskt verksamma imidazolderivat
SE394430B (sv) Forfarande for framstellning av indolylalkylaminer med terapeutisk verkan
SE373361B (sv) Forfarande for framstellning av n-fenacylkarbamater
FI56171B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva asylerade piperidin-, tetrahydropyridin- och pyridinderivat